AR045388A1 - Inhibidores del c-kit imidazopiridinicos n3-sustituidos - Google Patents
Inhibidores del c-kit imidazopiridinicos n3-sustituidosInfo
- Publication number
- AR045388A1 AR045388A1 ARP040103009A ARP040103009A AR045388A1 AR 045388 A1 AR045388 A1 AR 045388A1 AR P040103009 A ARP040103009 A AR P040103009A AR P040103009 A ARP040103009 A AR P040103009A AR 045388 A1 AR045388 A1 AR 045388A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cyclyl
- heterocyclyl
- nr3r31
- nr3c
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000004122 cyclic group Chemical group 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 2
- -1 N3-substituted imidazopyridine Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 108020004021 3-ketosteroid receptors Proteins 0.000 abstract 1
- 101100478293 Arabidopsis thaliana SR34 gene Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a inhibidores del c-kit imidazopiridinicos N3-sustituidos, o sales o N-óxidos aceptables para uso farmacéutico, útiles en el tratamiento del cáncer. Reivindicación 1: Un compuesto representado por la fórmula (1) en la cual R1 es: -NR3R31, -NR3C(O)R31, -NR3C(O)OR31, -NR3SO2R31, -OR3, -SR3, -SO2R3, -CO2R3, -CO2H, -CO-NR3R31, -N(alquilo C0-8)(alquilo C0-8), o -CN; excepto que cuando Y está presente y m> 1, entonces R1 es halógeno, -CN, NO2, -alquilo C0-8, -N(alquilo C0-8)(alquilo C0-8), alquenilo C2-8, alquinilo C2-8, -NR3R31, NR3C(O)R31, -NR3C(O)OR31, -NR3SO2R31, -OR3, -SR3, -SO2R3, -CO2R3, -CO2H, -CO-NR3R31, ciclilo, o un grupo heterociclilo; R2 es H, -alquilo C0-8, o -cicloalquilo C3-10; X es un grupo ciclilo o heterociclilo opcionalmente sustituido con uno o más sustituyentes elegidos de H, halógeno, NR32R33, -NR32COR33, -NR32CO2R33, -NR32SO2R33, -OR32, -SR32, -SO2R32, -SO2NR32R33, -CO2R32, -CO2H, -CONR32R33, -alquilo C0-8, -alquenilo C2-8, -alquinilo C2-8, -CN, -CF3, -OCF3, -NO2, oxo, ciclilo o un grupo heterociclilo, Y está ausente, o es uno de los grupos de fórmulas (2) en donde el punto de unión a X puede estar tanto a la izquierda como a la derecha de los conectores como se muestra; Ra y Rb cada uno independientemente es -alquilo C0-8 -alquenilo C2-8, -alquinilo C2-8, cicloalquilo C3-10, -cicloalquenilo C3-10, -alcoxi C1-8, -tioalquilo C1-8, carboxilo, -N(alquilo C0-8)(alquilo C0-8), oxo, o hidroxi; o tomados junto con el C al cual están unidos forman un anillo de 3-10 miembros saturado o parcialmente insaturado que contiene opcionalmente 0-4 N, O, S, SO, o SO2 en los nodos del anillo; Rc y Rd cada uno independientemente es -alquilo C0-8; -alquenilo C2-8, bencilo, o acilo; o tomados juntos, o con Ra o Rb, forman un anillo de 3-7 miembros saturado o parcialmente insaturado; m es 0,1 2, 3, 4 o 5; Z es un grupo ciclilo o heterociclilo, opcionalmente sustituido con uno o más sustituyentes elegidos de halógeno, un grupo NR34R35, NR34COR35, NR34CO2R35, NR34SO2R35, OR34, SR34, SO2R34, SO2NR34R35, CO2R34, CO2H, CONR34R35, alquil C0-8, alquenilo C2-8, alquinilo C2-8, CN, CF3, NO2, oxo, ciclilo o heterociclilo; o, cuando X e Y están presentes, Z puede ser -alquilo C1-8 o -alquilo C1-8-O-alquilo C1-8, y R3, R31, R32, R33, R34 y R35 son independientemente alquilo C0-8 opcionalmente sustituido con un sustituyente heterociclilo o OH; -alquilo C0-8-cicloalquilo C3-8, CF3,-alquilo C0-8-O-alquilo C0-8, -alquilo C0-8-N(alquilo C0-8)(alquilo C0-8), -alquilo C0-8-S(O)0-2-alquilo C0-8 o heterociclilo opcionalmente sustituido con -alquilo C0-8, ciclilo o sustituyente ciclilo sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49677603P | 2003-08-21 | 2003-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045388A1 true AR045388A1 (es) | 2005-10-26 |
Family
ID=34272515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103009A AR045388A1 (es) | 2003-08-21 | 2004-08-20 | Inhibidores del c-kit imidazopiridinicos n3-sustituidos |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1658289B1 (es) |
| JP (1) | JP2007502822A (es) |
| KR (1) | KR20060119871A (es) |
| CN (1) | CN1839132A (es) |
| AP (1) | AP2006003552A0 (es) |
| AR (1) | AR045388A1 (es) |
| AT (1) | ATE425977T1 (es) |
| AU (1) | AU2004268950A1 (es) |
| BR (1) | BRPI0413740A (es) |
| CA (1) | CA2536174A1 (es) |
| DE (1) | DE602004020073D1 (es) |
| IL (1) | IL173615A0 (es) |
| IS (1) | IS8318A (es) |
| MX (1) | MXPA06002019A (es) |
| MY (1) | MY138737A (es) |
| NO (1) | NO20060670L (es) |
| RU (1) | RU2006108799A (es) |
| SG (1) | SG131944A1 (es) |
| TW (1) | TW200519111A (es) |
| WO (1) | WO2005021544A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2672213C (en) | 2006-12-22 | 2016-02-16 | Astex Therapeutics Limited | Bicyclic amine derivatives as protein tyrosine kinase inhibitors |
| GB0625827D0 (en) * | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
| MX2009006706A (es) | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| MX2010011754A (es) | 2008-05-05 | 2010-12-06 | Sanofi Aventis | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos. |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| PL2308877T3 (pl) * | 2008-08-05 | 2014-07-31 | Daiichi Sankyo Co Ltd | Pochodne imidazopirydyn-2-onu |
| WO2010045276A2 (en) * | 2008-10-16 | 2010-04-22 | Cara Therapeutics, Inc. | Azabenzimidazolones |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| JP2012519281A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| CN102781940B (zh) * | 2009-12-30 | 2016-09-07 | 艾科尔公司 | 取代的咪唑并吡啶基-氨基吡啶化合物 |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| CN103748093B (zh) * | 2011-06-24 | 2016-06-01 | 艾科尔公司 | 被取代的咪唑并吡啶基-氨基吡啶化合物 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| BR112015014752B1 (pt) * | 2012-12-21 | 2022-07-05 | Plexxikon, Inc | Compostos e seus uso para modulação de cinase |
| WO2015148464A1 (en) * | 2014-03-24 | 2015-10-01 | Arqule Inc. | Process of preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3h-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine |
| EP3594206A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3594205A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| MX2022013597A (es) | 2020-04-29 | 2023-03-22 | Plexxikon Inc | Sintesis de compuestos heterociclicos. |
| WO2024117179A1 (en) * | 2022-11-30 | 2024-06-06 | Alivexis, Inc. | Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| TW251284B (es) * | 1992-11-02 | 1995-07-11 | Pfizer | |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| US6348032B1 (en) | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
| US6534535B1 (en) | 1999-08-12 | 2003-03-18 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| EP1214330A1 (en) | 1999-09-21 | 2002-06-19 | LION Bioscience AG | Benzimidazole derivatives and combinatorial libraries thereof |
| EP1255750A1 (en) | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
| WO2003020698A2 (en) * | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
-
2004
- 2004-08-16 KR KR1020067003586A patent/KR20060119871A/ko not_active Withdrawn
- 2004-08-16 AT AT04781205T patent/ATE425977T1/de not_active IP Right Cessation
- 2004-08-16 CA CA002536174A patent/CA2536174A1/en not_active Abandoned
- 2004-08-16 RU RU2006108799/04A patent/RU2006108799A/ru not_active Application Discontinuation
- 2004-08-16 EP EP04781205A patent/EP1658289B1/en not_active Expired - Lifetime
- 2004-08-16 CN CNA2004800240419A patent/CN1839132A/zh active Pending
- 2004-08-16 JP JP2006523956A patent/JP2007502822A/ja active Pending
- 2004-08-16 AU AU2004268950A patent/AU2004268950A1/en not_active Abandoned
- 2004-08-16 MX MXPA06002019A patent/MXPA06002019A/es unknown
- 2004-08-16 AP AP2006003552A patent/AP2006003552A0/xx unknown
- 2004-08-16 WO PCT/US2004/026483 patent/WO2005021544A2/en not_active Ceased
- 2004-08-16 BR BRPI0413740-0A patent/BRPI0413740A/pt not_active IP Right Cessation
- 2004-08-16 SG SG200702982-0A patent/SG131944A1/en unknown
- 2004-08-16 DE DE602004020073T patent/DE602004020073D1/de not_active Expired - Lifetime
- 2004-08-20 AR ARP040103009A patent/AR045388A1/es not_active Application Discontinuation
- 2004-08-20 MY MYPI20043423A patent/MY138737A/en unknown
- 2004-08-20 TW TW093125235A patent/TW200519111A/zh unknown
-
2006
- 2006-02-08 IL IL173615A patent/IL173615A0/en unknown
- 2006-02-10 NO NO20060670A patent/NO20060670L/no not_active Application Discontinuation
- 2006-02-21 IS IS8318A patent/IS8318A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE425977T1 (de) | 2009-04-15 |
| BRPI0413740A (pt) | 2006-10-24 |
| JP2007502822A (ja) | 2007-02-15 |
| RU2006108799A (ru) | 2006-07-27 |
| WO2005021544A3 (en) | 2005-06-16 |
| MXPA06002019A (es) | 2006-05-31 |
| IS8318A (is) | 2006-02-21 |
| DE602004020073D1 (de) | 2009-04-30 |
| SG131944A1 (en) | 2007-05-28 |
| KR20060119871A (ko) | 2006-11-24 |
| TW200519111A (en) | 2005-06-16 |
| CA2536174A1 (en) | 2005-03-10 |
| MY138737A (en) | 2009-07-31 |
| EP1658289B1 (en) | 2009-03-18 |
| EP1658289A2 (en) | 2006-05-24 |
| CN1839132A (zh) | 2006-09-27 |
| IL173615A0 (en) | 2006-07-05 |
| NO20060670L (no) | 2006-05-12 |
| WO2005021544A2 (en) | 2005-03-10 |
| AP2006003552A0 (en) | 2006-04-30 |
| AU2004268950A1 (en) | 2005-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045388A1 (es) | Inhibidores del c-kit imidazopiridinicos n3-sustituidos | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR047682A1 (es) | Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR045387A1 (es) | Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| CO6160312A2 (es) | Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico | |
| AR071823A1 (es) | Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos. | |
| AR078776A1 (es) | Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo | |
| AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
| AR056875A1 (es) | Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
| AR044342A1 (es) | Derivados de bencimidazol | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR035858A1 (es) | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 | |
| AR064657A1 (es) | 8- alquinilxantinas y derivados | |
| AR059030A1 (es) | Combinacion de derivados de triazina y estimuladores de la secrecion de insulina | |
| AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |